agree. net EBITDA margins will show a lot of shrinkage due to high costs in feb.
this is a long way from making sustainable ebitda.
there are a lot of competitors in this area in the usa, CBD is no IP protected.
the competitors will increase due to the hemp act- e.g. Canopy growth is coming in.
$3.40 is pricing in a lot of blue sky and acceleration in sales/and a slowdown of costs which is not occurring.
Ann: Quarterly Report and Appendix 4C, page-58
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.002(33.3%) |
Mkt cap ! $6.605M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $2.103K | 475.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 7670493 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 924824 | 4 |
View Market Depth
| Last trade - 14.04pm 29/11/2024 (20 minute delay) ? |
| EXL (ASX) Chart |
